Enwei Pharmaceuticals announced that the company's mid-term dividend plan for 2025 is to pay a cash dividend of 3.5 yuan for every 10 shares. According to the company's financial report for the third quarter of 2025, net profit attributable to shareholders of listed companies in the consolidated statement for the first three quarters of 2025 was RMB 3.5847 million, and the parent company's net profit for the first three quarters of 2025 was RMB 17.978,600. As of September 30, 2025, the consolidated statement's distributable profit was 357 million yuan, and the parent company's reported distributable profit was 142 million yuan. The company's distributable profit to shareholders is 142 million yuan. Based on the company's total share capital of 103 million shares on the date of the current board meeting and 102 million shares after deducting 1.0553 million shares already repurchased, the total dividends are estimated to be 35.6428 million yuan.

Enwei Pharmaceuticals announced that the company's mid-term dividend plan for 2025 is to pay a cash dividend of 3.5 yuan for every 10 shares. According to the company's financial report for the third quarter of 2025, net profit attributable to shareholders of listed companies in the consolidated statement for the first three quarters of 2025 was RMB 3.5847 million, and the parent company's net profit for the first three quarters of 2025 was RMB 17.978,600. As of September 30, 2025, the consolidated statement's distributable profit was 357 million yuan, and the parent company's reported distributable profit was 142 million yuan. The company's distributable profit to shareholders is 142 million yuan. Based on the company's total share capital of 103 million shares on the date of the current board meeting and 102 million shares after deducting 1.0553 million shares already repurchased, the total dividends are estimated to be 35.6428 million yuan.